MyBlueDots

VANCOUVER, British Columbia–(BUSINESS WIRE)– #biotech–Aspect Biosystems secures $115M Series B to advance bioprinted tissue therapeutics, accelerating development of functional cures for serious diseases

PEKÍN, ALAMEDA (California) y TAIPÉI–(BUSINESS WIRE)–Biocytogen (HKEX: 02315) y Acepodia (6976:TT) anunciaron hoy una alianza estratégica para evaluar de forma conjunta un programa de conjugados de anticuerpos-fármacos biespecíficos de carga doble (BsAD2C). Esta colaboración combina la plataforma RenLite® de Biocytogen con la tecnología de conjugación anticuerpo-fármaco doble (AD2C) de Acepodia para enfrentar algunos de los desafíos oncológicos más difíciles, como la heterogeneidad y la resis

SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation co

BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 15,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have

CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President &

NEWARK, Del.–(BUSINESS WIRE)– #CRISPR–CorriXR Therapeutics, Inc., a pioneering biotherapeutics company focused on oncology and innovative technologies to overcome drug resistance in solid tumors, announced that Jan Case has joined the Company as Chief Operating Officer. With over 25 years of experience in the biotechnology and pharmaceutical sectors, Case has driven operational excellence and strategic growth. As president of Cellicon Valley Consulting, she helped biotech start-ups, especially in the

HOUSTON–(BUSINESS WIRE)–SynergenX Health and HerKare, two leading providers of hormone therapy and wellness services, are raising awareness about the life-changing benefits of testosterone replacement therapy (TRT) for women. Over the past decade, testosterone prescriptions have increased by almost 50% in the United States alone. Testosterone, often associated with men, is vital for women’s health, playing a key role in energy, mood, libido, and muscle maintenance. As women age, testosterone

SYRACUSE, N.Y.–(BUSINESS WIRE)– #ClinicalTrials–Central New York Biotech Accelerator (CNYBAC). -– Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing proprietary carriers delivering tumoricidal therapies for metastatic and primary breast cancer, which may minimize patient side effects with the potential to increase survival rates, announced today in 2024 they nearly doubled their worldwide IP portfolio to 64 patents, spanning across 36 countries including the

RALEIGH, N.C. & OKLAHOMA CITY–(BUSINESS WIRE)–Lumata Health, a technology-driven healthcare innovator empowering ophthalmology practices to enhance continuous care for those at risk of blindness from chronic eye diseases, today formally announced its Clinical Advisory Board (CAB). The esteemed group of five leading ophthalmologists will provide strategic guidance to further Lumata’s mission of reducing preventable blindness through its turnkey, patient-centered continuous care platform. The C

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2024 at 8:15 a.m. PT in San Francisco, CA. A live webcast of the event will be accessible by visiting the “Events and Present